BIO Stock: Bio-Rad Laboratories, Inc. Stock Price, Analysis & Insights
Get live BIO stock price $291.01, comprehensive Bio-Rad Laboratories, Inc. stock analysis, charts, news, and expert forecast. Real-time BIO stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, an...
Company Information
- CEO
- Norman D. Schwartz
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 7700
Contact Information
- Website
- https://www.bio-rad.com
- Address
- 1000 Alfred Nobel Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 48.5)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Bio-Rad Laboratories, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Bio-Rad Laboratories, Inc.
- ⚠Investors should consider how Bio-Rad Laboratories, Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 48.5) requires strong growth to justify
Market Cap
7.87B
P/E Ratio (TTM)
48.50
Beta
1.08
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare BIO with peer companies:
- Price
- $170.50
- Market cap
- 12.21B
- Price
- $114.67
- Market cap
- 7.32B
- Price
- $186.29
- Market cap
- 8.97B
- Price
- $198.54
- Market cap
- 12.75B
- Price
- $80.86
- Market cap
- 10.91B
- Price
- $7.32
- Market cap
- 6.19B
- Price
- $89.72
- Market cap
- 7.50B
- Price
- $78.85
- Market cap
- 8.98B
- Price
- $179.95
- Market cap
- 9.42B
- Price
- $319.34
- Market cap
- 12.56B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.